Comparative Pharmacology
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus FEMOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus FEMOGEN.
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL vs FEMOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Femogen is a combination of estradiol (an estrogen) and norethindrone acetate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and promoting proliferation of the endometrium. Norethindrone acetate suppresses gonadotropin secretion and inhibits endometrial proliferation, reducing the risk of endometrial hyperplasia associated with estrogen therapy.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
1 mg orally once daily for 21 days, followed by 7 days off; for HRT, 1 mg orally once daily continuously.
None Documented
None Documented
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
Terminal half-life: 13.2 ± 2.3 hours; clinically, steady-state reached after 3-5 days.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Renal: 60-70% as glucuronide conjugates; Biliary/Fecal: 30-40% as metabolites; <1% unchanged.
Category D/X
Category C
Estrogen
Estrogen